Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
54 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Pulmonary Embolism - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Pulmonary Embolism - Pipeline Review, H1 2016', provides an overview of the Pulmonary Embolism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Embolism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pulmonary Embolism and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Pulmonary Embolism - The report reviews pipeline therapeutics for Pulmonary Embolism by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Pulmonary Embolism therapeutics and enlists all their major and minor projects - The report assesses Pulmonary Embolism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Pulmonary Embolism Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Pulmonary Embolism - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Pulmonary Embolism pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pulmonary Embolism Overview 6 Therapeutics Development 7 Pipeline Products for Pulmonary Embolism - Overview 7 Pipeline Products for Pulmonary Embolism - Comparative Analysis 8 Pulmonary Embolism - Therapeutics under Development by Companies 9 Pulmonary Embolism - Therapeutics under Investigation by Universities/Institutes 10 Pulmonary Embolism - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Pulmonary Embolism - Products under Development by Companies 14 Pulmonary Embolism - Products under Investigation by Universities/Institutes 15 Pulmonary Embolism - Companies Involved in Therapeutics Development 16 Accu-Break Pharmaceuticals, Inc. 16 Bristol-Myers Squibb Company 17 F. Hoffmann-La Roche Ltd. 18 Pulmonary Embolism - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 25 Drug Profiles 26 apixaban - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecule to Inhibit Cyclooxygenase and Glycoprotein IIb/IIIa for Pulmonary Embolism and Hematological Disorders - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 TMS-007 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 TRX-1 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 warfarin potassium - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Pulmonary Embolism - Recent Pipeline Updates 32 Pulmonary Embolism - Dormant Projects 40 Pulmonary Embolism - Discontinued Products 41 Pulmonary Embolism - Product Development Milestones 42 Featured News & Press Releases 42 Jan 18, 2016: Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials 42 Dec 10, 2015: AMPLIFY Post-Hoc Early Time Course Analysis Evaluated Recurrent Venous Thromboembolism, VTE-Related Death and Major Bleeding in Deep Vein Thrombosis and Pulmonary Embolism Patients Treated with Eliquis (apixaban) or Conventional Therapy 43 Nov 05, 2015: Janssen to Present Posters on rivaroxaban at the 2015 American Society of Hematology Annual Meeting 44 Mar 02, 2015: Findings to be Presented at Annual Scientific Session of the American College of Cardiology About an Additional Potential Reversal Strategy for and Real-World Safety Performance of XARELTO 44 Nov 26, 2014: ELIQUIS approved for treatment of venous thromboembolic events (Deep Vein Thrombosis [DVT], Pulmonary Embolism [PE]) and prevention of recurrent DVT and PE 45 Aug 22, 2014: U.S. FDA Approves Eliquis for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism, and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy 46 Aug 20, 2014: Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2014 47 Jul 29, 2014: European Commission Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 48 Jun 27, 2014: Eliquis (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE 49 May 28, 2014: Xarelto from Bayer Submitted in Japan for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism as well as for the Prevention of Recurrent Venous Thromboembolism 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables Number of Products under Development for Pulmonary Embolism, H1 2016 7 Number of Products under Development for Pulmonary Embolism - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Pulmonary Embolism - Pipeline by Accu-Break Pharmaceuticals, Inc., H1 2016 16 Pulmonary Embolism - Pipeline by Bristol-Myers Squibb Company, H1 2016 17 Pulmonary Embolism - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 25 Pulmonary Embolism Therapeutics - Recent Pipeline Updates, H1 2016 32 Pulmonary Embolism - Dormant Projects, H1 2016 40 Pulmonary Embolism - Discontinued Products, H1 2016 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
